Yukie Kidani1, Yasuo Miki2, Nana Nomimura3, Shiori Minakawa3, Norifumi Tanaka3, Hiroshi Miyoshi3, Koichi Wakabayashi2, Yoshiki Kudo3. 1. Department of Obstetrics and Gynecology, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan. Electronic address: ykidani@hiroshima-u.ac.jp. 2. Department of Neuropathology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki 036-8562, Japan. 3. Department of Obstetrics and Gynecology, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
Abstract
AIMS: Brain damage at birth can cause lifelong neurodevelopmental deficits. Recently, stem cell therapies have been used in several fields of medicine. We previously reported that CD133(+) cells, endothelial progenitor cells derived from human umbilical cord blood, induce nerve extension in an ex vivo hypoxic-ischemic encephalopathy model. Here, we used an in vivo model to examine the effect of CD133(+) cells in neonatal hypoxic-ischemic encephalopathy. MAIN METHODS: Hypoxic-ischemic brain lesions were induced in neonatal severe combined immunodeficiency mice using the Rice-Vannucci method. CD133(+) cells were administered by intraperitoneal injection 24h after injury. KEY FINDINGS: Immunohistochemical analysis revealed that intraperitoneally transplanted CD133(+) cells migrate towards the brain 48h after injection. Moreover, in CD133(+) cell-treated animals, motor function improved and the brain was protected from the hypoxic-ischemic insult compared with untreated animals. SIGNIFICANCE: Our results suggest that CD133(+) cells derived from human umbilical cord blood have therapeutic potential in neonatal hypoxic-ischemic encephalopathy.
AIMS: Brain damage at birth can cause lifelong neurodevelopmental deficits. Recently, stem cell therapies have been used in several fields of medicine. We previously reported that CD133(+) cells, endothelial progenitor cells derived from human umbilical cord blood, induce nerve extension in an ex vivo hypoxic-ischemicencephalopathy model. Here, we used an in vivo model to examine the effect of CD133(+) cells in neonatal hypoxic-ischemicencephalopathy. MAIN METHODS:Hypoxic-ischemic brain lesions were induced in neonatal severe combined immunodeficiencymice using the Rice-Vannucci method. CD133(+) cells were administered by intraperitoneal injection 24h after injury. KEY FINDINGS: Immunohistochemical analysis revealed that intraperitoneally transplanted CD133(+) cells migrate towards the brain 48h after injection. Moreover, in CD133(+) cell-treated animals, motor function improved and the brain was protected from the hypoxic-ischemic insult compared with untreated animals. SIGNIFICANCE: Our results suggest that CD133(+) cells derived from human umbilical cord blood have therapeutic potential in neonatal hypoxic-ischemicencephalopathy.
Authors: Tayla R Penny; Yen Pham; Amy E Sutherland; Joohyung Lee; Graham Jenkin; Michael C Fahey; Suzanne L Miller; Courtney A McDonald Journal: Sci Rep Date: 2021-08-04 Impact factor: 4.379